Rigel Pharmaceuticals
RIGL
93 hedge funds and large institutions have $193M invested in Rigel Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 18 closing their positions.
126% more capital invested
Capital invested by funds: $85.4M → $193M (+$107M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
8.46% more ownership
Funds ownership: 59.18% → 67.65% (+8.5%)
2% more funds holding
Funds holding: 91 → 93 (+2)
61% less call options, than puts
Call options by funds: $2.83M | Put options by funds: $7.22M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$12.1M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.19M |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$3.41M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$1.44M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.51M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.28M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.12M |
| 4 |
AC
Armistice Capital
New York
|
-$1.03M |
| 5 |
Jane Street
New York
|
-$944K |
RIGL Hedge Fund Activity: Q3 2024 in Review
93 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2024, worth a combined $193M — up 126% from $85.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RIGL positions and 18 closed out — a net gain of 3 holders — while 30 added to existing stakes and 24 trimmed.
The largest buyer was Invesco, adding an estimated $12.1M. The largest seller was Acadian Asset Management, cutting an estimated $1.51M.
- 93 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2024, up from 91 in Q2 2024.
- Funds reported $193M of Rigel Pharmaceuticals stock for Q3 2024, up 126% quarter-over-quarter.
- 21 funds opened new Rigel Pharmaceuticals positions in Q3 2024 and 18 closed out, a net change of +3 holders.
- The largest Rigel Pharmaceuticals buyer in Q3 2024 was Invesco, an estimated $12.1M added.
- The largest Rigel Pharmaceuticals seller in Q3 2024 was Acadian Asset Management, an estimated $1.51M sold.
Based on aggregated 13F filings for Q3 2024.